Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$10.74 USD
+0.46 (4.47%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $10.75 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Cogent Biosciences, Inc. (COGT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$16.91 | $26.00 | $8.00 | 64.49% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Cogent Biosciences, Inc. comes to $16.91. The forecasts range from a low of $8.00 to a high of $26.00. The average price target represents an increase of 64.49% from the last closing price of $10.28.
Analyst Price Targets (11)
Broker Rating
Cogent Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 1.45 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.45 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, eight are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 72.73% and 9.09% of all recommendations. A month ago, Strong Buy made up 72.73%, while Buy represented 9.09%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/COGT.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.45 | 1.45 | 1.45 | 1.45 | 1.45 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
7/24/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
5/24/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
5/24/2024 | Wedbush Securities | David M Nierengarten | Hold | Hold |
5/13/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
2/27/2024 | LifeSci Capital | Sam Slutsky | Strong Buy | Strong Buy |
2/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/26/2024 | Robert W. Baird & Co. | Colleen M Kusy | Not Available | Hold |
1/2/2024 | Guggenheim Securities | Michael Schmidt | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.45 |
ABR (Last week) | 1.45 |
# of Recs in ABR | 11 |
Average Target Price | $16.91 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -0.55 |